Journal: Urologia Internationalis
Submission Deadline: May 31, 2026
Urologic oncology is evolving rapidly, particularly in the context of personalized medicine. In urothelial carcinoma, the second most common malignancy of the urinary tract, significant therapeutic advances have been made in recent years. While targeted therapies such as FGFR inhibitors are used in biomarker-selected subgroups (FGFR2/3 alterations), the field of immunotherapy remains more complex.
Immune checkpoint inhibitors have become an established part of treatment for locally advanced disease in the perioperative setting or in metastatic disease; however, the absence of a reliable predictive and prognostic biomarker continues to limit their personalized application. Although PD-L1 expression and tumor mutational burden have been studied extensively, neither has demonstrated adequate sensitivity or specificity to effectively guide clinical decisions. Furthermore, recent clinical trials have shown that novel combination therapies, such as enfortumab vedotin (EV) with pembrolizumab or gemcitabine/cisplatin (GC) with nivolumab, have led to significant improvements in overall survival for patients with metastatic urothelial carcinoma. These encouraging results raise important clinical questions regarding the role of local therapy to the primary tumor, particularly in patients who achieve a complete response (CR) at metastatic sites.
In this emerging landscape, defining the optimal integration of systemic and local treatments is becoming increasingly relevant for individualized patient management. Authors are welcome to contribute Research, Review, and Systematic Review articles to this collection to further our understanding and advance the field.
Please select the option “Call for Papers: Urologic Cancer” when submitting your manuscript and mention this Call for Papers in your cover letter.
Article publication is subject to rigorous peer review in line with the journal's editorial policies. Please refer to our author guidelines for further details about the publication conditions.
As a hybrid journal, Urologia Internationalis supports Open Access publications. Corresponding authors can publish Open Access articles at no or reduced cost if they are associated with or employed by one of these universities/institutions.